- BIO CEO & Investor Conference, February 12, 2018, in New York City
- SunTrust Robinson Humphrey 4th Annual Orphan Drug Day, February 13, 2018, in New York City
The format of the BIO CEO & Investor Conference includes a brief presentation by management, participation in an immuno-oncology panel discussion, and one-on-one meetings with investors.
The format of the SunTrust Robinson Humphrey 4th Annual Orphan Drug Day is one-on-one meetings with investors only.
About NewLink Genetics Corporation
NewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics’ IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer. Indoximod, the company’s leading IDO inhibitor, is being evaluated in combination with treatment regimens including anti-PD-1/PD-L1 agents, cancer vaccines, and chemotherapy across multiple indications such as melanoma, pancreatic cancer and other malignancies. For more information, visit www.newlinkgenetics.com, and follow us on Twitter @NLNKGenetics.
Director of Investor Relations
VP, Integrated Communications
617-374-8800, ext. 105